Novo Nordisk price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan
JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...
World Trademark Review1d
How Novo Nordisk and Eli Lilly file for their well-known weight-loss brands
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
FiercePharma2d
Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4
Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Altinget.dk5d
Lars Boje er den evige outsider: Jeg er vant til at blive undervurderet
Borgernes Parti nærmer sig spærregrænsen, og partiet kræver en advokatundersøgelse af Mette Frederiksen for at støtte en ...